Hepatorenal Syndrome Management
Initial Treatment
- The initial treatment of choice for Hepatorenal Syndrome (HRS) is vasoconstrictor therapy with terlipressin plus albumin infusion, as recommended by the American Association for the Study of Liver Diseases (AASLD) 1, 2, 3
- Alternative treatment options include Norepinephrine + Albumin, with Norepinephrine: 0.5-3.0 mg/h continuous IV infusion and Albumin: 20-40 g/day IV, and Midodrine + Octreotide + Albumin, with Midodrine: 7.5-12.5 mg orally three times daily, Octreotide: 100-200 μg subcutaneously three times daily, and Albumin: 20-40 g/day IV, as suggested by the American Journal of Transplantation 4
Diagnosis and Classification
- Diagnosis of HRS-AKI requires cirrhosis with ascites, AKI according to ICA-AKI criteria, no response after diuretic withdrawal and volume expansion, absence of shock, no recent use of nephrotoxic drugs, and no signs of structural kidney injury, as recommended by the European Association for the Study of the Liver (EASL) 5
- The International Club of Ascites (ICA) revised classification categorizes HRS as HRS-AKI (formerly Type 1 HRS) and HRS-NAKI (Non-AKI, formerly Type 2 HRS), with HRS-AKI defined as an increase in serum creatinine ≥0.3 mg/dL within 48 hours or ≥1.5 times from baseline within 7 days 2, 5
Treatment Duration and Response
- Treatment should be continued for up to 14 days, with response rates higher with lower baseline serum creatinine, and consideration of discontinuing therapy if no response after 4 days with maximum tolerated doses 1, 2
- Complete response is defined as return of serum creatinine to within 0.3 mg/dL of baseline, and partial response is defined as regression of AKI stage with serum creatinine ≥0.3 mg/dL above baseline 2
Medication Dosages
| Medication | Dosage |
|---|---|
| Albumin | 1 g/kg body weight per day for two consecutive days (maximum 100 g/day) |
| Terlipressin | 0.5-2.0 mg IV every 4-6 hours or continuous infusion of 2-12 mg/24h |
| Norepinephrine | 0.5-3.0 mg/h continuous IV infusion |
| Midodrine | 7.5-12.5 mg orally TID |
| Octreotide | 100-200 μg SQ TID |
Contraindications and Adverse Effects
- Contraindications to terlipressin include serum creatinine ≥5 mg/dL, oxygen saturation <90%, and severe cardiovascular disease 2
- Contraindications for albumin use include history of pulmonary edema, severe cardiac dysfunction, and severe hyponatremia, and should be used cautiously in these patients, as suggested by the American Gastroenterological Association and the American Heart Association 6, 2
- Adverse effects of terlipressin include ischemic complications, respiratory complications such as pulmonary edema, and gastrointestinal complications such as abdominal pain and diarrhea 2, 3
Monitoring and Complications
- Patients on terlipressin and albumin should be monitored for cardiovascular, respiratory, and peripheral circulation complications, as well as fluid status and signs of volume overload, which can occur in up to 43% of patients treated with terlipressin and albumin 7, 6, 2
- Patients on albumin and vasoconstrictor therapy should be monitored for signs of volume overload and pulmonary edema, with regular assessment of cardiovascular parameters and daily evaluation of serum creatinine 1, 3
Renal Replacement Therapy and Liver Transplantation
- Renal replacement therapy should be considered for patients awaiting liver transplantation who have worsening renal function, electrolyte disturbances, or increasing volume overload unresponsive to vasoconstrictor therapy, as recommended by the AASLD 1
- Liver transplantation is the most effective definitive treatment for HRS-AKI, and renal replacement therapy (RRT) may be indicated for AKI secondary to acute tubular necrosis, HRS-AKI in potential liver transplant candidates, or severe electrolyte/acid-base disturbances or volume overload 2, 3